JP2016514697A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016514697A5 JP2016514697A5 JP2016503226A JP2016503226A JP2016514697A5 JP 2016514697 A5 JP2016514697 A5 JP 2016514697A5 JP 2016503226 A JP2016503226 A JP 2016503226A JP 2016503226 A JP2016503226 A JP 2016503226A JP 2016514697 A5 JP2016514697 A5 JP 2016514697A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- deficiency
- aryl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 76
- 150000001875 compounds Chemical class 0.000 claims description 56
- 239000000203 mixture Substances 0.000 claims description 28
- 125000003118 aryl group Chemical group 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 15
- 239000000090 biomarker Substances 0.000 claims description 12
- 230000007812 deficiency Effects 0.000 claims description 12
- 239000012453 solvate Substances 0.000 claims description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 239000001301 oxygen Substances 0.000 claims description 7
- 208000013200 Stress disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 125000001188 haloalkyl group Chemical group 0.000 claims description 6
- 230000002438 mitochondrial effect Effects 0.000 claims description 6
- 230000036542 oxidative stress Effects 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 208000029560 autism spectrum disease Diseases 0.000 claims description 5
- 125000001072 heteroaryl group Chemical group 0.000 claims description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 4
- 208000001992 Autosomal Dominant Optic Atrophy Diseases 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 4
- 206010058892 Carnitine deficiency Diseases 0.000 claims description 4
- 208000002155 Cytochrome-c Oxidase Deficiency Diseases 0.000 claims description 4
- 208000024412 Friedreich ataxia Diseases 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 108700006159 Long-chain acyl-CoA dehydrogenase deficiency Proteins 0.000 claims description 4
- 208000014413 Maternally-inherited diabetes and deafness Diseases 0.000 claims description 4
- 108700000232 Medium chain acyl CoA dehydrogenase deficiency Proteins 0.000 claims description 4
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 claims description 4
- 201000002169 Mitochondrial myopathy Diseases 0.000 claims description 4
- 208000012202 Pervasive developmental disease Diseases 0.000 claims description 4
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 208000028867 ischemia Diseases 0.000 claims description 4
- 208000004687 long chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 208000005548 medium chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims description 4
- 208000012268 mitochondrial disease Diseases 0.000 claims description 4
- 208000016505 systemic primary carnitine deficiency disease Diseases 0.000 claims description 4
- -1 —O—C 1 -C 4 Chemical group 0.000 claims description 4
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims description 3
- 206010010904 Convulsion Diseases 0.000 claims description 3
- 206010061323 Optic neuropathy Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 230000004064 dysfunction Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 208000020911 optic nerve disease Diseases 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 208000010444 Acidosis Diseases 0.000 claims description 2
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 claims description 2
- 208000018126 Adrenomyeloneuropathy Diseases 0.000 claims description 2
- 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010003591 Ataxia Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 208000014644 Brain disease Diseases 0.000 claims description 2
- 108700005857 Carnitine palmitoyl transferase 1A deficiency Proteins 0.000 claims description 2
- 208000005359 Carnitine palmitoyl transferase 1A deficiency Diseases 0.000 claims description 2
- 108700005858 Carnitine palmitoyl transferase 2 deficiency Proteins 0.000 claims description 2
- 201000002929 Carnitine palmitoyltransferase II deficiency Diseases 0.000 claims description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 2
- 208000021075 Creatine deficiency syndrome Diseases 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 claims description 2
- 201000010374 Down Syndrome Diseases 0.000 claims description 2
- 102000015782 Electron Transport Complex III Human genes 0.000 claims description 2
- 108010024882 Electron Transport Complex III Proteins 0.000 claims description 2
- 208000032274 Encephalopathy Diseases 0.000 claims description 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 208000028782 Hereditary disease Diseases 0.000 claims description 2
- 101000804964 Homo sapiens DNA polymerase subunit gamma-1 Proteins 0.000 claims description 2
- 101001083553 Homo sapiens Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Proteins 0.000 claims description 2
- 101000841267 Homo sapiens Long chain 3-hydroxyacyl-CoA dehydrogenase Proteins 0.000 claims description 2
- 101000595929 Homo sapiens POLG alternative reading frame Proteins 0.000 claims description 2
- 101000603761 Homo sapiens Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase Proteins 0.000 claims description 2
- 102100030358 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Human genes 0.000 claims description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 2
- 208000025069 Juvenile Huntington disease Diseases 0.000 claims description 2
- 102100029107 Long chain 3-hydroxyacyl-CoA dehydrogenase Human genes 0.000 claims description 2
- 108010027062 Long-Chain Acyl-CoA Dehydrogenase Proteins 0.000 claims description 2
- 102000018653 Long-Chain Acyl-CoA Dehydrogenase Human genes 0.000 claims description 2
- 102100021644 Long-chain specific acyl-CoA dehydrogenase, mitochondrial Human genes 0.000 claims description 2
- 208000035719 Maculopathy Diseases 0.000 claims description 2
- 208000024556 Mendelian disease Diseases 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- 206010059521 Methylmalonic aciduria Diseases 0.000 claims description 2
- 208000019022 Mood disease Diseases 0.000 claims description 2
- 208000026072 Motor neurone disease Diseases 0.000 claims description 2
- 208000001769 Multiple Acyl Coenzyme A Dehydrogenase Deficiency Diseases 0.000 claims description 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 2
- 208000021642 Muscular disease Diseases 0.000 claims description 2
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims description 2
- 201000009623 Myopathy Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 102100035196 POLG alternative reading frame Human genes 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000013234 Pearson syndrome Diseases 0.000 claims description 2
- 102100038551 Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase Human genes 0.000 claims description 2
- 208000002009 Pyruvate Dehydrogenase Complex Deficiency Disease Diseases 0.000 claims description 2
- 206010038540 Renal tubular necrosis Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 206010038923 Retinopathy Diseases 0.000 claims description 2
- 208000006289 Rett Syndrome Diseases 0.000 claims description 2
- 208000002903 Thalassemia Diseases 0.000 claims description 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 2
- 208000016620 Tourette disease Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
- 230000007950 acidosis Effects 0.000 claims description 2
- 208000026545 acidosis disease Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 201000004010 carnitine palmitoyltransferase I deficiency Diseases 0.000 claims description 2
- 201000008609 cerebral creatine deficiency syndrome Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000035110 classic form autosomal dominant optic atrophy Diseases 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 201000009028 early myoclonic encephalopathy Diseases 0.000 claims description 2
- 206010016256 fatigue Diseases 0.000 claims description 2
- 239000000835 fiber Substances 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 208000034737 hemoglobinopathy Diseases 0.000 claims description 2
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 208000006443 lactic acidosis Diseases 0.000 claims description 2
- 208000038015 macular disease Diseases 0.000 claims description 2
- 201000003694 methylmalonic acidemia Diseases 0.000 claims description 2
- 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 claims description 2
- 208000005264 motor neuron disease Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 108010007425 oligomycin sensitivity conferring protein Proteins 0.000 claims description 2
- 206010030875 ophthalmoplegia Diseases 0.000 claims description 2
- 208000001749 optic atrophy Diseases 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 231100000572 poisoning Toxicity 0.000 claims description 2
- 230000000607 poisoning effect Effects 0.000 claims description 2
- 230000000750 progressive effect Effects 0.000 claims description 2
- 201000006473 pyruvate decarboxylase deficiency Diseases 0.000 claims description 2
- 208000015445 pyruvate dehydrogenase deficiency Diseases 0.000 claims description 2
- 230000035806 respiratory chain Effects 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 208000001392 short chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims description 2
- 208000007056 sickle cell anemia Diseases 0.000 claims description 2
- 208000023516 stroke disease Diseases 0.000 claims description 2
- 230000009529 traumatic brain injury Effects 0.000 claims description 2
- 230000000007 visual effect Effects 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims 3
- 208000012130 acyl-CoA dehydrogenase deficiency Diseases 0.000 claims 2
- 208000024825 childhood disintegrative disease Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 201000005943 Barth syndrome Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 206010011903 Deafness traumatic Diseases 0.000 claims 1
- 108020005196 Mitochondrial DNA Proteins 0.000 claims 1
- 208000002946 Noise-Induced Hearing Loss Diseases 0.000 claims 1
- 206010057430 Retinal injury Diseases 0.000 claims 1
- ASARMUCNOOHMLO-WLORSUFZSA-L cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2s)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O ASARMUCNOOHMLO-WLORSUFZSA-L 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 230000003389 potentiating effect Effects 0.000 claims 1
- 230000010410 reperfusion Effects 0.000 claims 1
- 238000005728 strengthening Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 11
- 0 *c(c(*)c1N=C(C(*)=C2*)C3=C(*)C2=O)c(*)c(*=C)c1*3=C Chemical compound *c(c(*)c1N=C(C(*)=C2*)C3=C(*)C2=O)c(*)c(*=C)c1*3=C 0.000 description 2
- 241000283070 Equus zebra Species 0.000 description 1
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 description 1
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 1
- 206010051403 Mitochondrial DNA deletion Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 208000004622 abetalipoproteinemia Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000036546 leukodystrophy Diseases 0.000 description 1
- 201000007998 methylmalonic aciduria and homocystinuria type cblC Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- QAQREVBBADEHPA-IEXPHMLFSA-N propionyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 QAQREVBBADEHPA-IEXPHMLFSA-N 0.000 description 1
- 208000019880 recessive mitochondrial ataxia syndrome Diseases 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/838,372 US20140275045A1 (en) | 2013-03-15 | 2013-03-15 | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| US13/838,372 | 2013-03-15 | ||
| PCT/US2014/029811 WO2014145119A1 (en) | 2013-03-15 | 2014-03-14 | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016514697A JP2016514697A (ja) | 2016-05-23 |
| JP2016514697A5 true JP2016514697A5 (https=) | 2017-04-27 |
Family
ID=50680171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503226A Pending JP2016514697A (ja) | 2013-03-15 | 2014-03-14 | 酸化ストレス障害の処置のためのフェナジン−３−オンおよびフェノチアジン−３−オン誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20140275045A1 (https=) |
| EP (1) | EP2970151A1 (https=) |
| JP (1) | JP2016514697A (https=) |
| CA (1) | CA2906154A1 (https=) |
| HK (1) | HK1220450A1 (https=) |
| WO (1) | WO2014145119A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2471530B1 (en) | 2005-06-01 | 2017-01-11 | Edison Pharmaceuticals, Inc. | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| WO2009061744A2 (en) | 2007-11-06 | 2009-05-14 | Edison Pharmaceuticals, Inc. | 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases |
| EA023618B1 (ru) | 2008-01-08 | 2016-06-30 | Эдисон Фармасьютикалз, Инк. | Производные (гет)арил-п-хинона для лечения митохондриальных болезней |
| EP2344142B1 (en) | 2008-09-10 | 2024-06-26 | PTC Therapeutics, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
| CA2741767C (en) | 2008-10-28 | 2017-09-12 | Ptc Therapeutics, Inc. | Process for the production of alpha-tocotrienol and derivatives |
| PL2424495T3 (pl) | 2009-04-28 | 2018-06-29 | Bioelectron Technology Corporation | Leczenie dziedzicznej neuropatii nerwów wzrokowych lebera i dominującego zaniku nerwu wzrokowego chinonami tokotrienolu |
| WO2012174286A1 (en) | 2011-06-14 | 2012-12-20 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
| JP2014520894A (ja) | 2011-07-19 | 2014-08-25 | エジソン ファーマシューティカルズ， インコーポレイテッド | 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法 |
| CA2883879A1 (en) | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Quinone derivatives for use in the modulation of redox status of individuals |
| US10189830B2 (en) | 2013-03-15 | 2019-01-29 | Bioelectron Technology Corporation | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders |
| US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
| AU2015364640B2 (en) | 2014-12-16 | 2020-08-13 | Ptc Therapeutics, Inc. | Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide |
| WO2016133995A1 (en) * | 2015-02-17 | 2016-08-25 | Arizona Board Of Regents On Behalf Of Arizona State University | Phenothiazine analogues as mitochondrial therapeutic agents |
| US10364227B2 (en) | 2015-02-17 | 2019-07-30 | Arizona Board Of Regents On Behalf Of Arizona State University | Therapeutic compounds |
| EP3390377B1 (en) | 2015-12-16 | 2026-03-25 | PTC Therapeutics, Inc. | Improved methods for enriching alpha-tocotrienol from mixed tocol compositions |
| WO2017106803A1 (en) | 2015-12-17 | 2017-06-22 | Bioelectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| US12570622B2 (en) | 2016-08-25 | 2026-03-10 | Arizona Board Of Regents On Behalf Of Arizona State University | Therapeutic compounds |
| US11390605B2 (en) | 2016-08-25 | 2022-07-19 | Arizona Board Of Regents On Behalf Of Arizona State University | Substituted pyrimidine compounds as multifunctional radical quenchers and their uses |
| WO2018039487A1 (en) * | 2016-08-25 | 2018-03-01 | Arizona Board Of Regents On Behalf Of Arizona State University | Therapeutic compounds |
| JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| JP6958860B2 (ja) | 2017-11-07 | 2021-11-02 | 学校法人自治医科大学 | ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途 |
| KR20210076956A (ko) | 2018-10-17 | 2021-06-24 | 피티씨 테라퓨틱스, 인크. | α-시누클레인병증, 타우병증 및 기타 장애를 억제 및 치료하기 위한 2,3,5-트리메틸-6-노닐사이클로헥사-2,5-디엔-1,4-디온 |
| PE20240893A1 (es) | 2021-07-08 | 2024-04-24 | Ptc Therapeutics Inc | Composiciones farmaceuticas que comprenden 2,3,5-trimetil-6-nonilciclohexa-2,5-dien-1,4-diona |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE840115L (en) * | 1983-01-21 | 1984-07-21 | Merck Frosst Canada Inc | Phenothiazine derivatives and analogs |
| US4667032A (en) * | 1983-01-21 | 1987-05-19 | Merck Frosst Canada, Inc. | Phenothiazone derivatives and analogs |
| US4548927A (en) * | 1983-05-25 | 1985-10-22 | Eaton John W | Method and agents for raising animal tolerance to oxidant stress-inducing antibiotics |
| JPS60209520A (ja) * | 1984-03-19 | 1985-10-22 | メルク エンド カムパニー インコーポレーテツド | リポキシゲナーゼ阻害剤の細胞保護的使用 |
| NZ513547A (en) | 2001-08-13 | 2002-09-27 | Antipodean Biotechnology Ltd | Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone) |
| GB0204232D0 (en) | 2002-02-22 | 2002-04-10 | Isis Innovation | Assay |
| DE60211875T2 (de) | 2002-07-01 | 2006-10-26 | Santhera Pharmaceuticals (Schweiz) Ag | Screeningverfahren und Verbindungen zur Behandlung von Friedreich ataxia |
| CA2830581A1 (en) * | 2011-04-04 | 2012-10-11 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Multifunctional radical quenchers for the treatment of mitochondrial dysfunction |
-
2013
- 2013-03-15 US US13/838,372 patent/US20140275045A1/en not_active Abandoned
-
2014
- 2014-03-14 WO PCT/US2014/029811 patent/WO2014145119A1/en not_active Ceased
- 2014-03-14 JP JP2016503226A patent/JP2016514697A/ja active Pending
- 2014-03-14 HK HK16108426.9A patent/HK1220450A1/zh unknown
- 2014-03-14 EP EP14722468.7A patent/EP2970151A1/en not_active Withdrawn
- 2014-03-14 CA CA2906154A patent/CA2906154A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016514697A5 (https=) | ||
| JP2016515527A5 (https=) | ||
| JP2016515526A5 (https=) | ||
| JP2016520621A5 (https=) | ||
| JP2015533794A5 (https=) | ||
| JP2019504018A5 (https=) | ||
| JP2018500326A5 (https=) | ||
| JP2016525093A5 (https=) | ||
| JP2013056919A5 (https=) | ||
| JP2013091672A5 (https=) | ||
| MX353957B (es) | Carboxamidas heterociclicas fungicidas. | |
| JP2021524440A5 (https=) | ||
| JP2015500843A5 (https=) | ||
| JP2014520072A5 (https=) | ||
| NZ601967A (en) | Pde10 inhibitors and related compositions and methods | |
| PH12013501197B1 (en) | Indeno-fused ring compounds | |
| JP2010526831A5 (https=) | ||
| RU2013147998A (ru) | Способ получения дронедарона посредством n-бутилирования | |
| MX374409B (es) | Derivados de etinilo como moduladores del receptor de glutamato metabotrópico. | |
| MX2021011972A (es) | Derivados de 2-(feniloxi o feniltio)pirimidina como herbicidas. | |
| RU2016151420A (ru) | Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий | |
| MX380421B (es) | Compuestos herbicidas de pirimidiniloxi benceno sustituido. | |
| JP2018505228A5 (https=) | ||
| JP2017534665A5 (https=) | ||
| AR106589A1 (es) | Derivados de indolin-2-ona |